A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo

This is a study that is being conducted in order to assess the efficacy of microneedling as a stand-alone treatment for vitiligo. Vitiligo is an autoimmune depigmentation disease of the skin that is characterized by the destruction of epidermal melanocytes by CD8+ T cells. The pathogenesis of Vitiligo has been linked to autoimmunity, oxidative stress, and genetic susceptibility.

Study Overview

• Status: Completed
• Conditions: Vitiligo
• Intervention / Treatment: Device: Skinpen Precision System

Detailed Description

Microneedling is a minimally invasive technique developed for skin rejuvenation. In the treatment for vitiligo, the procedure causes micro-inflammations on the epidermis and enhances melanocytes and keratinocytes migration. This process leads to the stimulation and repigmentation of vitiligo areas. Several topical therapies such as Tacrolimus and 5-Fluorouracilused in conjunction with microneedling have yielded favorable repigmentation results. This study aims to evaluate the repigmentation rates of microneedled vitiligo patches without any topical medications other than sunscreen.

There will be a total of 8 -12 treatments over the course of 244 days, with subjects receiving a treatment every 2 weeks.

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Texas
    • Dallas, Texas, United States, 75234
      • Crown Laboratories

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Adult male or female, ages 18 through 60.
2. Clinical diagnosis of stable Vitiligo (no changes within the past 6 months) on any of the following body areas: face, neck, trunk, extremities, hands, feet (excluding digits).
3. Subjects in generally good health and free of any conditions which, in the opinion of the investigator, would interfere with the study assessments.
4. Subjects willing to discontinue all current therapies for vitiligo for the duration of the study.
5. Women of childbearing potential agree to take a urine pregnancy test at the Baseline visit and Final visit.
6. Individuals that are willing to provide written informed consent and are able to read, speak, write and understand the informed consent document.
7. Willingness to cooperate and participate by following study requirements for the duration of the study and to report any changes in health status or medications, adverse event symptoms, or reactions immediately.

Exclusion Criteria:

1. Individuals diagnosed with known allergies to facial or general skin care products.
2. Individuals who have presence of an active systemic or local skin disease, apart from vitiligo, that may affect wound healing. Uncontrolled disease such as asthma, diabetes, hyperthyroidism, medically significant hypertension or hypothyroidism. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, etc.
3. Individuals with sensitivity to topical lidocaine, stainless steel, nickel, or chromium
4. Individuals who have a recent or current history of inflammatory skin disease or cancerous/pre-cancerous lesion.
5. Subjects currently or within the past 3 months on Vitiligo topical or systemic treatments.
6. Use of skin lighteners or bleaching agents; hydroquinone, phenol peels or harsh chemicals.
7. Individuals who have the inability to understand instructions or to give informed consent.
8. Individuals who have a history of chronic drug or alcohol abuse.
9. Individuals undergoing concurrent therapy that, in the Investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.
10. Individuals who are current smokers.
11. Individuals who are nursing, pregnant, or planning to become pregnant during the study according to subject self-report.
12. Individuals with a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined by study documentation.
13. Individuals with any planned surgeries, overnight hospitalization, and/or invasive medical procedures during the course of the study.
14. Individuals who are currently participating in any other study involving the use of investigational device or drugs at another research facility or doctor's office within 4 weeks prior to inclusion into the study.
15. Individuals who have any condition, which in the opinion of the Investigator makes the patient unable to complete the study per protocol (e.g. patients not likely to avoid other facial cosmetic treatments; patients not likely to stay in the study for its duration because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable, or patients who have a concomitant condition that may develop symptoms that might confuse or confound study treatments or assessments)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Microneedling with Skinpen Precision System; Skinpen precision system will be used in accordance with the instructions in the IFU on the treatment area. A numbing cream will be applied at least 20-30 minutes before the Skinpen Precision system treatment is done. The affected areas will be treated at depths of up to 2.50mm. Treatment depth will be recorded for each treatment at every visit. Subjects will be dispensed with the Blue Lizard sunscreen and trained on proper use.

Device: Skinpen Precision System; Subjects will receive a total of 8-12 treatments with the Skinpen Precision system targeting their Vitiligo lesions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Physician's Global Assessment (PGA)	PGA to be completed starting at Visit 2 and on, prior to each treatment. The primary endpoint is to achieve Grade 2, 3 or 4 on the PGA Scale comparing photographs from baseline to visits 12, 13, and 14. This is a 5 Grade Repigmentation Scale. This assessment uses a scale of G0-G4. This global assessment will be done by the investigator starting at Visit 2 and afterwards. G4 Excellent > 75% Repigmentation G3 Very Good 50%-75% Repigmentation G2 Good 25%-50% Repigmentation G1 Satisfactory <25% Repigmentation G0 Poor No Repigmentation	Through Study Completion, over the course of 244 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Subject's assessment of their pre and post-treatment images using the Vitiligo Noticeability Scale (VNS)	Subject's assessment of their pre and post-treatment images using the Vitiligo Noticeability Scale. A score of 3,4, or 5 indicates the success of the treatment.	Through Study Completion, over the course of 244 days

Collaborators and Investigators

• Sponsor: Crown Laboratories, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): July 29, 2021
• Primary Completion (Actual): November 21, 2022
• Study Completion (Actual): January 24, 2023

Study Registration Dates

• First Submitted: August 26, 2021
• First Submitted That Met QC Criteria: September 20, 2021
• First Posted (Actual): September 22, 2021

Study Record Updates

• Last Update Posted (Actual): May 24, 2023
• Last Update Submitted That Met QC Criteria: May 23, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Pigmentation Disorders; Hypopigmentation; Vitiligo
• Other Study ID Numbers: CL-VL-21-04

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No